share_log

港股扫描 | 腾盛博药本周累涨逾61%;和铂医药涨超11%

Hong Kong stock scan | Tenshengbo Pharmaceutical rose more than 61% this week; and Platinum Pharmaceutical rose more than 11%

富途資訊 ·  Nov 17, 2021 15:39  · Movers

Editor / Wudong

According to Futu News on November 17, the main index of Hong Kong stocks maintained wide volatility after the correction. As of press release, the Hang Seng Index fell 0.5% and the Hang Seng Technology Index fell 0.8%.

big

Education stocks rose generally, New Oriental Education & Technology Group online rose more than 16%, this month rose more than 62%, New Oriental Education & Technology Group rose more than 8%, thinking music education rose more than 7%, people's livelihood education, Tianli education, China Oriental education rose more than 4%, Hope Education and Zhonghui Group rose more than 3%.

big

Tengsheng Bo medicine rose more than 14%, up more than 61% this week. CICC released a research report saying that it was first rated as "outperforming industry" by Tengsheng Bo Pharmaceuticals-B (02137), with a target price of HK $31. Other biomedical B stocks also generally rose, and Platinum Pharmaceuticals rose more than 11%, Zai Lab Limited rose more than 6%, Yasheng Pharmaceutical rose more than 5%, Gui Chuang Tongqiao and Development Pharmaceutical rose more than 4%, and Nuocheng Jianhua and Kang Fang Bio rose nearly 3%.

big

The auto parts sector showed a strong performance, with Minshi Group up more than 12%, Nestor up more than 7%, 100 million and holding up more than 6%, Ganfeng Lithium up more than 5%, and Lijin Technology up more than 1%.

big

According to the Futuo Niuniu Hong Kong stock trading hot list today, the top stocks include Tencent, Kuaishou Technology, BABA, Meituan, Razer, XIAOMI Group, NONGFU SPRING CO., LTD., Semiconductor Manufacturing International Corporation and so on.

big

It is forbidden to copy or reprint without the permission of Futu.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment